{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-021087","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.142790+00:00","generated_at":"2026-06-05T11:23:50.184902+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kura Oncology Q4 net loss $42.8M; ziftomenib KOMET-001 enrollment on track for mid-2024","bullets":["Net loss for Q4 2023 was $42.8M vs $33.1M in Q4 2022; full year loss $152.6M vs $135.8M.","Cash and investments $424M at Dec 31, 2023; pro forma $570M after Jan 2024 private placement, runway into 2027.","Enrollment of 85 patients in registration-directed KOMET-001 trial of ziftomenib for NPM1-m AML expected by mid-2024.","Preliminary KOMET-007 data: 100% CR in frontline NPM1-m/KMT2A-r AML with 7+3; 53% ORR in R/R with ven/aza; no differentiation syndrome.","First patient dosed in KOMET-008 (ziftomenib + gilteritinib, FLAG-IDA or LDAC); collaboration with Mirati for KO-2806 + adagrasib."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-021087","json":"https://secwatch.observer/filing/0000950170-24-021087.json","markdown":"https://secwatch.observer/filing/0000950170-24-021087.md","text":"https://secwatch.observer/filing/0000950170-24-021087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/0000950170-24-021087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/kura-20240227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T11:23:50.184902+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b65bb818c25c42048abb8876d4110f52494fd622","claim":"Kura Oncology, Inc. reported financial results for fourth quarter and year ended December 31, 2023.","evidence_excerpt":"On February 27, 2024, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and year ended December 31, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017024021087/0000950170-24-021087-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}